Nektar Therapeutics [NASDAQ: NKTR] closed the trading session at $12.70 on 01/06/22. The day’s price range saw the stock hit a low of $12.03, while the highest price level was $12.78. The company report on January 5, 2022 that Nektar Therapeutics’ President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference.
Nektar Therapeutics’ (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 3:00 p.m. Eastern Time. The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. This webcast will be available for replay until February 11, 2022.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
The stocks have a year to date performance of -6.00 percent and weekly performance of -9.29 percent. The stock has been moved at -26.89 percent over the last six months. The stock has performed 4.27 percent around the most recent 30 days and changed -24.58 percent over the most recent 3-months.
If compared to the average trading volume of 2.15M shares, NKTR reached to a volume of 2601619 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Nektar Therapeutics [NKTR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NKTR shares is $25.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NKTR stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Benchmark Company have made an estimate for Nektar Therapeutics shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 08, 2021. While these analysts kept the previous recommendation, BofA Securities raised their target price to Neutral. The new note on the price target was released on September 10, 2021, representing the official price target for Nektar Therapeutics stock. Previously, the target price had yet another raise from $22 to $24, while Stifel kept a Buy rating on NKTR stock.
The Average True Range (ATR) for Nektar Therapeutics is set at 0.75, with the Price to Sales ratio for NKTR stock in the period of the last 12 months amounting to 24.19. The Price to Book ratio for the last quarter was 2.92, with the Price to Cash per share for the same quarter was set at 4.82.
NKTR stock trade performance evaluation
Nektar Therapeutics [NKTR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.29. With this latest performance, NKTR shares gained by 4.27% in over the last four-week period, additionally sinking by -26.89% over the last 6 months – not to mention a drop of -31.72% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NKTR stock in for the last two-week period is set at 40.70, with the RSI for the last a single of trading hit 34.01, and the three-weeks RSI is set at 43.11 for Nektar Therapeutics [NKTR]. The present Moving Average for the last 50 days of trading for this stock 13.48, while it was recorded at 13.27 for the last single week of trading, and 16.33 for the last 200 days.
Nektar Therapeutics [NKTR]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Nektar Therapeutics [NKTR] shares currently have an operating margin of -248.45 and a Gross Margin at +81.21. Nektar Therapeutics’s Net Margin is presently recorded at -290.65.
Return on Total Capital for NKTR is now -23.35, given the latest momentum, and Return on Invested Capital for the company is -29.84. Return on Equity for this stock declined to -35.80, with Return on Assets sitting at -25.28. When it comes to the capital structure of this company, Nektar Therapeutics [NKTR] has a Total Debt to Total Equity ratio set at 29.74. Additionally, NKTR Total Debt to Total Capital is recorded at 22.92, with Total Debt to Total Assets ending up at 20.82. Long-Term Debt to Equity for the company is recorded at 28.45, with the Long-Term Debt to Total Capital now at 21.93.
Reflecting on the efficiency of the workforce at the company, Nektar Therapeutics [NKTR] managed to generate an average of -$618,997 per employee. Receivables Turnover for the company is 3.79 with a Total Asset Turnover recorded at a value of 0.09.Nektar Therapeutics’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.90 and a Current Ratio set at 7.00.
Earnings per share (EPS) analysis for Nektar Therapeutics [NKTR] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NKTR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Nektar Therapeutics go to -7.30%.
Nektar Therapeutics [NKTR]: Insider Ownership positions
There are presently around $2,121 million, or 92.20% of NKTR stock, in the hands of institutional investors. The top three institutional holders of NKTR stocks are: INVESCO LTD. with ownership of 35,671,187, which is approximately 0.036% of the company’s market cap and around 1.40% of the total institutional ownership; BLACKROCK INC., holding 18,844,244 shares of the stock with an approximate value of $240.64 million in NKTR stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $229.6 million in NKTR stock with ownership of nearly -0.565% of the company’s market capitalization.
Positions in Nektar Therapeutics stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 103 institutional holders increased their position in Nektar Therapeutics [NASDAQ:NKTR] by around 5,436,047 shares. Additionally, 105 investors decreased positions by around 5,511,821 shares, while 52 investors held positions by with 155,128,036 shares. The mentioned changes placed institutional holdings at 166,075,904 shares, according to the latest SEC report filing. NKTR stock had 28 new institutional investments in for a total of 2,104,665 shares, while 26 institutional investors sold positions of 1,482,492 shares during the same period.